Targets › ADI1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2027.
Catalyzes 2 different reactions between oxygen and the acireductone 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene) depending upon the metal bound in the active site (By similarity). Fe-containing acireductone dioxygenase (Fe-ARD) produces formate and 2-keto-4-methylthiobutyrate (KMTB), the alpha-ketoacid precursor of methionine in the methionine recycle pathway. (UniProt, Q9BV57)
Open in Phaseline: the race on ADI1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chongqing Peg-Bio Biopharm | PA5 Pegylated Arginine Deiminase Dimer | ADI1 | Phase 1 | Advanced Solid Tumors | Feb 2027 |
Advanced Solid Tumors (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.